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Red blood cell (RBC) supply for transfusion has been severely constrained by the limited availability of donor blood and the
emergence of infection and contamination issues. Alternatively, hematopoietic stem cells (HSCs) from human organs have been
increasingly considered as safe and effective blood source. Several methods have been studied to obtain mature RBCs from CD34+
hematopoietic stem cells via in vitro culture. Among them, human cord blood (CB) and granulocyte colony-stimulating factor-
mobilized adult peripheral blood (mPB) are common adult stem cells used for allogeneic transplantation. Our present study focuses
on comparing CB- and mPB-derived stem cells in differentiation from CD34+ cells into mature RBCs. By using CD34+ cells from
cord blood and G-CSF mobilized peripheral blood, we showed in vitro RBC generation of artificial red blood cells. Our results
demonstrate that CB- and mPB-derived CD34+ hematopoietic stem cells have similar characteristics when cultured under the
same conditions, but differ considerably with respect to expression levels of various genes and hemoglobin development. This
study is the first to compare the characteristics of CB- and mPB-derived erythrocytes. The results support the idea that CB and
mPB, despite some similarities, possess different erythropoietic potentials in in vitro culture systems.
1. Introduction
Red blood cell transfusion is a well-established and essen-
tial therapy for patients with severe anemia. However, the
worldwide supply of allogeneic blood faces a serious shortage,
and there are many patients around the world whose survival
depends on blood transfusion. Around 92 million blood
donations are collected annually from all types of blood
donors (voluntary unpaid, family/replacement, and paid),
but in the report of 39 counties of 159 countries on their
collections, donated blood is still not routinely tested for
transfusion-transmissible infections (TTIs) including HIV,
hepatitis B, hepatitis C, and syphilis [1]. Nevertheless, blood
transfusion saves lives, but the transfusion of unsafe blood
puts lives at risk because HIV or hepatitis infections can be
transmitted to patients through transfusion. However, the
financial consequence of discarding unsafe blood creates yet
another burden in developing countries.
Research performed on stem cells, specifically
hematopoietic stem cells (HSCs), holds promise for the
production of mature red blood cells in large quantities
through differentiation induction. The classic source
of HSCs has been the bone marrow, but bone marrow
procurement of cells is an invasive process with risks.
The artificial RBCs from stem cells in vitro culture can be
generated from sources such as embryonic stem cells (ESCs)
[2], induced pluripotent stem cells (iPSs) [3], cord blood
(CB) [4–6], and peripheral blood (PB) [7]. Of these, ESCs
and iPSCs are the least promising due to the low generation
efficiency and long-term in vitro culture cost hindrances.
Currently, granulocyte colony-stimulating factor- (G-CSF-)
mobilized peripheral blood (mPB) and CB are therefore
Hindawi Publishing Corporation
BioMed Research International
Volume 2014, Article ID 435215, 9 pages
http://dx.doi.org/10.1155/2014/435215
2 BioMed Research International
widely researched as a potential alternate source for stem
cell procurement. However, this has not been a widespread
standard of therapy, and the characteristics of mature red
blood cells derived from HSCs after mass production are not
yet well known. Our study focuses on comparing CB- and
mPB-derived stem cells with respect to their characteristics
and function after differentiation.
2. Materials and Methods
2.1. CD34+ HSC Isolation, Culture, and Erythropoietic Dif-
ferentiation. CB samples from normal full-term deliveries
(𝑛 = 7) were collected in a bag (Green Cross Corp.,
Yong-in, Korea) containing 24.5mL of citrate phosphate
dextrose A (CPDA-1). Five milliliters of G-CSF-mPB was
obtained (𝑛 = 7) with the written informed consent of
normal voluntary allogeneic HSC donors. This study was
approved by Severance Hospital IRB (IRB number 4-2011-
0081).TheCD34+ cells from both sources were isolated using
a MACS isolation kit (density, 1.077; Pharmacia Biotech,
Uppsala, Sweden) using an antibody against CD34 according
to the manufacturer’s instructions. And the sorted CD34+
cells were cultured at a density of 1 × 105 cells/mL in a
stroma-free condition for 17–21 days as described previously
[8, 9]. Briefly, from day 0 to 7, sorted CD34+ cells were
continually cultured in serum-free conditioned erythrocyte
culture medium with 100 ng/mL SCF (Peprotech, Rehovot,
Israel), 10 ng/mL IL-3 (Peprotech), and 6 IU/mL recombinant
EPO (Recormon Epoetin beta, Roche) with a half-volume
medium change twice a week. Serum-free culture medium
consisted of StemPro-34 SFM Complete Medium (Gibco,
Grad Island, NY) supplemented with 1% bovine serum albu-
min (Sigma), 150 𝜇g/mL iron-saturated human transferrin
(Sigma), 50𝜇g/mL insulin (Sigma), 90 ng/mL ferrous nitrate
(Sigma), 2mMol/L L-glutamine (Sigma), 1.6 × 10−4mol/L
monothioglycerol (Sigma), 30.8 𝜇M/L vitamin C (Sigma),
2 𝜇g/mL cholesterol (Sigma), and 1% penicillin-streptomycin
solution (Gibco). In the second 7-day period of culture, the
medium was replaced with serum-free conditioned medium
with 3 IU/mL of recombinant EPO, 50 ng/mL of SCF, and
10 ng/mL of IL-3 for expansion and differentiation. During
days 15–18 of culture, only one cytokine (EPO, at 2 IU/mL)
was used for erythrocyte differentiation, and poloxamer 188
(Pluronic F68 (F68), Sigma; MW 8400) was added at a
concentration of 0.05%.No cytokineswere added during days
19–21 of culture, and only poloxamer 188 was added during
this period. At the end of each phase, cultured cells were
counted using a hemocytometer. The trypan blue stain was
used in all cell counts, and only viable cells are included in the
fold expansion results. All cultures were maintained at 37∘C
in a humidified atmosphere of 5% CO
2
.
2.2. Assessment of Cell Morphology. Cell morphology was
assessed using slides prepared by Cytospin using a cyto-
centrifuge (Cytospin 3, Shandon Scientific, Tokyo, Japan)
at 800 rpm for 4min followed by Wright-Giemsa staining.
Pictures of the stained cells were taken with a digital camera
(DP70, Olympus, Tokyo, Japan) at 400x magnification.
2.3. Differential Counting of Cultured Erythroblasts. Five
differential countings were enumerated as proerythroblasts,
early and late basophilic erythroblasts, polychromatic ery-
throblasts, and orthochromatic erythroblasts at 1000x mag-
nification.
2.4. Flow Cytometric Analyses of Erythroid Markers. For flow
cytometric analyses of cell surface antigens, a total of 1 × 105
cells were stained with phycoerythrin- (PE-) or fluorescein
isothiocyanate- (FITC-) conjugated mouse anti-human anti-
bodies against CD45, CD34, CD71, and glycophorin A (GpA)
for 15min, washed, resuspended in FACS buffer, and analyzed
using aCell LabQuanta SC (BeckmanCoulter, Fullerton, CA,
USA) using a 488 nm wavelength laser. Cells were analyzed
using two-color flow cytometry through WinMDI 2.9. The
antibody combinations usedwere CD45-FITC/CD34-PE and
CD71-FITC/GpA-PE, using G1-FITC/G1-PE as a control. All
fluorescent conjugated monoclonal antibodies used were
purchased from BD Biosciences (San Jose, CA).
2.5. Quantitative Real-Time Polymerase Chain Reaction. To
evaluate gene expression levels during erythrocyte differen-
tiation from different sources, we harvested over 1 × 106
cells from cultured erythrocytes at 7, 10, 14, and 17 days and
isolated total RNA for quantitative polymerase chain reaction
(PCR). Gene expression levels were quantified using the Light
Cycler 480 Real-time PCR System (Roche Applied Science).
Quantitative real-time polymerase chain reaction (qPCR)
was performed using Light Cycler 480 SYBR Green I Master
mix (Roche Applied Science) according to themanufacturer’s
instructions. Primers were designed [10, 11] and generated
by Bioneer (Korea) (Table 1). Total RNA (800 ng) was used
to generate first-strand cDNA using the Maxime RT Premix
Kit (Intron Biotech). Differences between the Cp (crossing
point) values of actin and target mRNAs for each sample
were used to calculate ΔCp values. The ΔCp values derived
from the isolated, undifferentiated CD34+ cells were used
as control ΔCp values. Relative expression levels between
samples and controls were determined using the formula:
relative expression level = 2−(𝑆ΔCp−𝐶ΔCp). Comparative real-
time PCR with primers specific for GATA1, GATA2, EKLF,
eALAS, and SCL/Tall (Table 1) was performed in triplicate.
Reactions were performed at 95∘C for 10min, followed by 45
cycles of 95∘C for 30 s, 60∘C for 30 s, and 72∘C for 30 s.
2.6. Functional Analysis of Hemoglobin. We used a Hemox-
Analyzer (TCS, Medical Products Division, Southampton,
PA) to measure the oxygen binding and dissociation abilities
of the hemoglobin produced in mature erythrocytes derived
from the mPB and cord blood. Hemox-Analyzer is an auto-
matic system for recording blood oxygen equilibrium curves
and related phenomena [12]. The operating principle of the
Hemox-Analyzer is based on dual-wavelength spectropho-
tometry for the measurement of the optical properties of
hemoglobin and a Clark electrode for measuring the oxygen
partial pressure in millimeters of mercury. The resulting
signals from both measuring systems are fed to the 𝑋-𝑌
recorder. Both the P
50
value and observation of the fine
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Figure 1: Comparison of cell growth in PB- and CB-derived CD34+ cell cultures. Stem cells were cultured for 21 days and counted at the end
of each phase. (a) Erythroid cell amplification (mean ± standard deviation) of mPB- and CB-derived CD34+ cells. (b) Numbers of total cells
expanded from cultures of mPB- and CB-derived CD34+ cells. CB-CD34+ cells exhibit higher amplification efficiency than mPB cells. ∗𝑃 <
0.001.
Table 1: Real-time polymerase chain reaction primers.
Gene Primer sequence
𝛽-actin
Forward primer
Reverse primer
5󸀠-ATTGGCAATGAGCGGTTC-3󸀠
5󸀠-GGATGCCACAGGACTCCAT-3󸀠
GATA-1
Forward primer
Reverse primer
5󸀠-CACTGAGCTTGCCACATCC-3󸀠
5󸀠-ATGGAGCCTCTGGGGATTA-3󸀠
GATA-2
Forward primer
Reverse primer
5󸀠-GGCAGAACCGACCACTCATC-3󸀠
5󸀠-TCTGACAATTTGCACAACAGGTG-3󸀠
eALAS
Forward primer
Reverse primer
5󸀠-GATGTGAAGGCTTTCAAGACAGA-3󸀠
5󸀠-GGAAAATGGCTTCCTTAGGC-3󸀠
EKLF
Forward primer
Reverse primer
5󸀠-ATCGAGTGAAGAGGAGACCTTCC-3󸀠
5󸀠-TGAAGATACGCCGCACAACTT-3󸀠
SCL/Tal1
Forward primer
Reverse primer
5󸀠-ACACACAGGATGACTTCCTC-3󸀠
5󸀠-CCCATGTCCTGCGC-3󸀠
structure of the curve can furnish information about the
delivery of oxygen to tissues. CD34+ cells derived from CB
and mPB that were cultured for 17 days in three separate
phases were analyzed using this system. Normal red blood
cells were used as a control.
2.7. Capillary Zone Electrophoresis. After 17 days of culture, 1
× 108 cells were collected and assessed by capillary zone elec-
trophoresis. Capillary zone electrophoresis was performed as
described previously using the Sebia Capillary system (Sebia,
Norcross, GA) [13]. Differentiated erythrocytes (5 × 107cells)
were centrifuged at 5,000 rpm for 5 minutes. Thereafter, the
culture medium was removed, and the erythrocyte pellet was
vortexed for 5 s. Electrophoresis was performed in alkaline
buffer (pH 9.4) provided by the manufacturer (Sebia), with
separation primarily due to the pH of the solution and
endosmosis. The hemoglobin was measured at a wavelength
of 415 nm. Electrophoretograms were recorded with the
location of specific hemoglobin in specific zones.
2.8. Statistical Analysis. Student’s 𝑡-test was performed using
Excel (Microsoft). 𝑃 values less than 0.05 were considered
statistically significant.
3. Results
3.1. In Vitro Culture Supports the Differentiation of Ery-
throcytes. The number of cell divisions observed signifi-
cantly increased during the second phase of the culture
period. Compared to mPB-CD34+ cells, CB-CD34+ cells
have greater proliferative capacity during days 10–21of culture
(Figure 1(a)). This difference led to CB cultures achieving
a greater total number of cells than that of mPB cultures
(636,038 ± 182,817 versus 83,256 ± 8,858). Cell growth in CB
cell cultures exceeded that of mPB cell cultures in the second
phase and early third phase of culture (Figure 1(b)). Following
erythropoietic differentiation, decreased cell size, nuclear
condensation, and nuclear extrusion were confirmed by
Wright-Giemsa staining. Although there were no significant
differences found, our results show that, in the blood type
composition count, the CB HSCs have more multipotency
while mPB-CD34+ cells show earlier differentiation into
mature erythrocytes (Figure 2(a)). These results demonstrate
thatmPB- andCB-derived CD34+HSCs have similar growth
patterns andmorphological characteristics, butmPB-derived
CD34+ cells show faster maturation than CB-derived CD34+
cells (Figure 2(b)).
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Figure 2: Comparison of cell morphological changes in mPB- and CB-derived CD34+ cell cultures. CD34+ cells selected from mPB and
CB were cultured for 21 days in vitro. Morphological changes in differentiated cells from both sources were similar. No remarkably different
patterns were found in the Giemsa staining photos (a). Based on the erythrocyte cell type counting at the end of each phase, the mPB-derived
cells matured more rapidly than the cells derived from CB, even though cells from both sources have similar maturation patterns (b).
3.2. Similar Immunophenotypic Patterns. CD34 and CD45
marker dramatically decreased and finally disappeared from
the cells during differentiation, while GPA expression
increased during the 21 days of culture. Although CD71
expression increased until early in the third phase of culture,
it gradually decreased following final maturation (Figure 3).
From the immunophenotypic data, we found no significant
differences between mPB- and CB-derived CD34+ cells
during erythroid cell maturation.
3.3. Different mRNA Expression Levels. From our data, we
can see different patterns in the differentiation of mPB- and
CB-derived CD34+ cells. Our data clearly show that GATA-1
expression gradually increases during erythrocyte differenti-
ation, especially in CB cells, while GATA-2 expression grad-
ually decreases following cell maturation. The erythrocyte-
specific isoforms ALAS and SCL/Tall are upregulated during
erythrocyte differentiation and, in particular, show higher
levels inmPB-derived cells than inCB-derived cells. Only one
factor, EKLF, which is a 𝛽-globin gene transcription factor,
increased during erythrocyte differentiation inmPB cells but,
in contrast, decreased during differentiation of CB-derived
cells (Figure 4). These results clearly demonstrate that mPB-
derived CD34+ cells differentiate faster into erythrocytes
with Hb-𝛽 production than CB cells. At the same time,
under these in vitro culture conditions, CB-derived CD34+
hematopoietic cells exhibit higher multipotency than mPB
cells.
3.4. Different Hemoglobin Type Development in mPB- and
CB-Derived CD34+ Cells. Over 80% of the hemoglobin pro-
duced by CB-derived CD34+ cells was hemoglobin subtype
HbF, while only 17.5% was subtype HbA. Over 95% of the
hemoglobin generated by mPB-derived cells was subtype
HbA (Figure 5).
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Figure 3: Phenotypic markers in erythrocytes differentiated from mPB- and CB-derived CD34+ cells. Cells (3 × 105) from the end of each
phase of culture were stained, and hematopoietic and erythropoietic markers were measured. Flow cytometry results show similar patterns
in the cultured cells from both sources and no significant differences.
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Figure 4: Erythrocyte-specific gene expression in mPB and CB cells. At the end of each phase of culture, cells were harvested, and total
RNA was extracted for quantitative PCR.The expression of GATA-1, GATA-2, eALAS, EKLF, and SCL/Tal1 was measured by real-time PCR.
The results show an increasing pattern for the GATA-1 transcript and a decreasing pattern for GATA-2, which did not significantly differ
between mPB and CB cells. EKLF, eALAs, and SCL/Tall expression levels increased during differentiation but were significantly greater in
mPB-derived erythrocytes than in those from CB.
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Figure 5: Electrophoretic determination of main hemoglobin subtypes in differentiated mPB and CB cells. Capillary zone electrophoresis
shows distinct patterns of hemoglobin subtype expression between differentiated mPB and CB cells. About 80% of the hemoglobin produced
by CB-CD34-derived erythrocytes is HbF, while only 17.5% is HbA. However, 95.5% of the hemoglobin produced by mPB-CD34-derived
erythrocytes is HbA.
3.5. Similar Hemoglobin Dissociation Curve with Mature
RBCs from mPB and CB Cells. While erythrocytes derived
from each source have different combinations of HbA and
HbF, similar hemoglobin dissociation curve was observed
(Figure 6). Apart from this hemoglobin subtype variation,
this result clearly shows that in vitro cultured RBCs can
produce hemoglobin with oxygen binding and dissociation
abilities equivalent to red blood cells produced in vivo.
4. Discussion
The shortage of blood supply and the ever-growing demand
for blood transfusion represent a significant emerging issue in
transfusionmedicine. Shortage of donated blood and the risk
of infection have created limitations in the availability of red
blood cells available for transfusion. More recently, isolated
CD34+ cells from human umbilical CB obtained from dis-
carded maternity products and G-CSF-mPB obtained from
healthy volunteers through leukapheresis have emerged as
potential alternative sources of HSCs. The HSCs collected
from both sources have high rates of proliferation and
capacities for differentiation and create mature RBCs under
the proper culture conditions through three phases of in
vitro culture. We note that, though both types of stem
cells show similar characteristics in general growth patterns
with morphological and immunophenotypic changes, they
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Figure 6: Hemox analysis in mPB and CB cells cultured for 21 days. Differentiated erythrocytes were harvested at the end of the 21 days
of culture, and oxygen equilibria were measured by Hemox-Analyzer. Erythrocytes derived from mPB and from CB both show greater
oxygenation abilities compared with normal human blood. There are no significant differences between differentiated mPB and CB cells.
show different characteristics in gene expression levels and
hemoglobin subtype production.
Our results show that bothmPB- and CB-derived CD34+
cells began to proliferate extremely quickly during 7–14 days
of culture. However, both cell sources produce similar total
cell numbers after 21 days of culture. And morphological
changes in differentiated cells from both sources were similar,
and no remarkable differences were found during the culture
except when comparing cell differentiation rates. The mPB
cells seemed to mature earlier than CB cells. These results
show that mPB cells, from circulating blood, possess more
progenitor cells than CB and have the ability of rapid
differentiation into the mature RBCs. Following cell growth
at the end of each cell culture phase, mPB- and CB-derived
CD34+, GPA, and CD70 (transferrin receptor) expression
showed similar patterns in flow cytometry analyses. These
data are consistent with previous results regarding erythro-
cyte induction mechanisms [8, 14]. To confirm whether the
initial exposition of cells is due to different sources derived
differentiation, gene expression profiles were analyzed by
quantitative RT-PCR. GATA-1 is a transcription factor that
determines erythroid differentiation, survival, and 𝛽-globin
gene expression [15]. GATA-2 inhibits GATA-1 function.
GATA-2 expression exhibited a downregulation following
erythropoietin stimulation, and its levels were higher in
cultured mPB cells. This can be explained in earlier dif-
ferentiation into mature RBCs in mPB source cells than
in CB. This finding is also consistent with the result of
differential counts that mPB showed faster shift from pronor-
moblasts to orthochromatic normoblasts in comparison to
CB. Ikonomi et al. have previously shown that GATA-2
preferentially increases 𝛾-globin gene expression, indicating
that the prolonged expression of GATA-2 contributes to the
early increase in 𝛾-globin in CB [16]. EKLF binds specifically
to the 𝛽-globin promoter and is critical in establishing
chromatin structure for high-level 𝛽-globin transcription via
its acetylation by CREB binding protein [17]. SCL/Tall is
required for the progression of erythroid differentiation, and
enforced expression of SCL/Tall increases 𝛽-globin expres-
sion and BFU-E and CFU-E production [18]. Because these
transcription factors are closely related to increased 𝛽-globin
gene expression, changes in their expression may account
for the delay and reduction of 𝛽-globin expression in CB-
derived differentiated cells. The HbA- and HbF-related gene
expression tests exhibit different expression levels depending
on the cell source.We culturedmPB- andCB-derived CD34+
cells through three phases, harvested them after 17 days
of culture, and analyzed them by hemoglobin type testing.
These results clearly demonstrated different subtypes of
hemoglobin expressed bymPB- andCB-derivedmature cells.
CB-derived cells mostly express HbF and mPB-derived cells
mainly express HbA, but, based on these data, the original
sources of these cells appear to possess different propensities
for hemoglobin production patterns. These results demon-
strate that hemoglobin subtypes are not related to culture
conditions and culture time but are strongly affected by the
source material. To evaluate the function of the differentiated
mPB and CB cells, CD34+ cells derived from each source
were expanded and differentiated to large cell numbers of
up to a total of 5 × 107 cells, and oxygen equilibria were
measured by Hemox-Analyzer. From the result, the oxygen
dissociation curves indicate that the cells from both sources
do not significantly differ from one another with respect
to hemoglobin function. Although the types of hemoglobin
expression differed between CB- and mPB-derived mature
cells, the oxygen binding and dissociation curves may be
similar due to variation among adult type hemoglobin, fetal
type hemoglobin, or mixture of both types in vitro culture
processing after 17 days of culture. The cultured cells, indeed,
have slightly greater deoxygenation functionalities compared
with normal cells, which showed the immaturity in shift to
left.
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In summary, mPB and CB are undoubtedly excellent
sources for mature RBC production and may be key in
contributing to a solution for the RBC supply shortage
problem. Our study shows that, despite similar phenotypes
and functionalities following erythrocytematuration, the two
are discrete in that they show different Hb types and gene
expression levels. This study demonstrates distinctions that
should be taken into account when choosing the source of
HSCs for artificial mature RBC production form stem cells.
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